Fangsheng Pharmaceutical announced that the company held a briefing on the 2026 semi-annual results and cash dividends to disclose that in the first half of 2026, it achieved operating income of 958 million yuan, an increase of 14.80%; net profit to mother was 198 million yuan, an increase of 16.79%; and net profit after deducting non-return to mother was 174 million yuan, an increase of 23.07% year on year. It is planned to pay 0.20 yuan per share for the half year of 2026, and the dividend amount is expected to be 88 million yuan, accounting for 44.43% of net profit returned to mother in the first half of the year. Revenue from cardiovascular and cerebrovascular drugs increased 50.01% year-on-year in the first half of the year, and revenue from musculoskeletal medicine increased 10.80% year-on-year.

Fangsheng Pharmaceutical announced that the company held a briefing on the 2026 semi-annual results and cash dividends to disclose that in the first half of 2026, it achieved operating income of 958 million yuan, an increase of 14.80%; net profit to mother was 198 million yuan, an increase of 16.79%; and net profit after deducting non-return to mother was 174 million yuan, an increase of 23.07% year on year. It is planned to pay out 0.20 yuan per share for the half year of 2026, and the dividend amount is expected to be 88 million yuan, accounting for 44.43% of net profit returned to mother in the first half of the year. Revenue from cardiovascular and cerebrovascular drugs increased 50.01% year-on-year in the first half of the year, and revenue from musculoskeletal medicine increased 10.80% year-on-year.